Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02471911 · ClinicalTrials.gov registry record · Phase 1
KPT-330 Plus RICE for Relapsed/Refractory Aggressive B-Cell Lymphoma
A Phase 1 study, sponsored by Weill Medical College of Cornell University.
- Completed
- Registry status
- Phase 1
- Development phase
- 22
- Enrollment target
NCT02471911: Completed Phase 1 study, sponsored by Weill Medical College of Cornell University.
NCT02471911 is a Phase 1 study that has completed, run by Weill Medical College of Cornell University. The registered enrollment target is 22 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (63% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02471911, a Phase 1 study, has completed, sponsored by Weill Medical College of Cornell University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 22 participants
- Enrollment target
Study Summary
This study evaluates the addition of selinexor (KPT-330) to RICE chemotherapy in the treatment of relapsed and refractory aggressive B-Cell Lymphoma, with the goal of improved response rates (as compared to RICE chemotherapy alone).
Primary Outcome
The highest dose level at which no more than 1 or 6 patients presents with a dose-limiting toxicity (DLT) during the first 6 cycles of treatment
Interventions
- DRUG Carboplatin
- DRUG Rituximab
- DRUG Etoposide
- DRUG Ifosfamide
- DRUG KPT-330
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2015-12-11 |
| Est. Completion | 2021-10-14 |
| Phase | Phase 1 |
What the finished NCT02471911 record still lists
NCT02471911 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 22 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (63% lower).
The record links to 0 conditions, and to 5 interventions - of which Carboplatin is the first listed.
NCT02471911 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02471911 about?
NCT02471911 is a clinical study titled "KPT-330 Plus RICE for Relapsed/Refractory Aggressive B-Cell Lymphoma". This study evaluates the addition of selinexor (KPT-330) to RICE chemotherapy in the treatment of relapsed and refractory aggressive B-Cell Lymphoma, with the goal of improved response rates (as compared to RICE chemotherapy alone).
What is the current status of trial NCT02471911?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 22 participants. The study started on 2015-12-11. Estimated completion is 2021-10-14.
What interventions are being tested in trial NCT02471911?
The interventions under investigation include: Carboplatin (DRUG), Rituximab (DRUG), Etoposide (DRUG), Ifosfamide (DRUG), KPT-330 (DRUG).
Who is sponsoring clinical trial NCT02471911?
This trial is sponsored by Weill Medical College of Cornell University, which has 701 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02471911's enrollment target sits among peer trials
22 1601st of 2000 higher than 386 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02508038 · 22 participants · Phase 1
Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors
- NCT03099356 · 22 participants · Phase 2
Cyclophosphamide and Sirolimus for the Treatment of Metastatic, RAI-refractory, Differentiated Thyroid Cancer
- NCT03676647 · 22 participants
Diagnostic DNA Methylation Signature in Diagnosing Thyroid Cancer After Fine-Needle Aspiration in Patients With Thyroid Nodules
- NCT04569591 · 22 participants · NA
DDAVP for Pituitary Adenoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI